Invasive infection due to Trichosporon cutaneum in patients with hematologic malignancies

Cancer

Volumn 82, Issue 3, 1998, Pages 484-487

  Kataoka Nishimura, Shigeko ^a   Akiyama, Hideki ^a   Saku, Kazue ^a   Kashiwa, Machiko ^a   Mori, Shinichiro ^a   Tanikawa, Shu ^a   Sakamaki, Hisashi ^a   Onozawa, Yasusuke ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Hematologic malignancy; Neutropenia; Systemic infection; Trichosporon

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; LEUKEMIA; MALE; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; TRICHOSPORON CUTANEUM;

ADULT; AGED; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYCOSES; OPPORTUNISTIC INFECTIONS; TRICHOSPORON;

EID: 0032005324     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980201)82:3<484::AID-CNCR9>3.0.CO;2-P     Document Type: Article

References (12)

1. Hoy J, Hsu KC, Rolston K, Hopfer RL, Luna M, Bodey GP. Trichosporon beigelii infection: a review. Rev Infect Dis 1986; 8:959-67.
2. Walsh TJ. Trichosporonosis. Infect Dis Clin North Am 1989; 3:43-52.
3. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard. Document M27-P. Villanova, PA: National Committee for Clinical Laboratory Standards, 1992.
4. Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporon in patients with neoplastic disease. Medicine 1986; 65:268-79.
5. Walling DM, McGraw DJ, Merz WG, Karp JE, Hutchins GM. Disseminated infection with Trichosporon beigelii. Rev Infect Dis 1987; 9:1013-9.
6. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, et al. Trichosporon beigelii: an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28:1616-22.
7. Perparim K, Nagai H, Hashimoto A, Goto Y, Tashiro T, Nasu M. In vitro susceptibility of Trichosporon beigelii to antifungal agents. J Chemother 1996; 8:445-8.
8. Anaissie E, Gokaslan A, Hachem R, Rubin R, Grigin G, Robinson R, et al. Azole therapy for Trichosporon: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992; 15:781-7.
9. Haupt HM, Merz WG, Beschoner WE, Vaughan WP, Saral R. Colonization and infection with Trichosporon species in the immunocompromised host. J Infect Dis 1983; 147:199-203.
10. Grauer ME, Bokemeyer C, Bautsch W, Freund M, Link H. Successful treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor. Infection 1994; 22:283-6.
11. Lyman CA, Garrett KF, Pizzo PA, Walsh TJ. Response of human polymorphonuclear leukocytes and monocytes to Trichosporon beigelii: Host defence against an emerging opportunistic pathogen. J Infect Dis 1994; 170:1557-65.
12. Karyotakis NC, Dignani MC, Hachem R, Anaissie EJ. Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections. Antimicrob Agents Chemother 1995; 39:571-3.